🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

Recruitingn/aAges 18 Years - anyAllNorthwestern University
NCT04616131 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Biopsy or cytology proven adenocarcinoma of the pancreas * No clinical evidence of metastatic disease on imaging * Age 18 or older * Receiving chemotherapy for non-metastatic pancreatic cancer Exclusion Criteria: * Biopsy proven metastatic disease
💊

What it tests

  • Not listed
📍

Where

3 sites
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, United States
Northwestern Medicine Cancer Center Delnor
Geneva, United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy